Brian Olshansky, MD
Cardiovascular Disease · Iowa City, IANPI 1962483347
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Lundbeck LLC at 50.3% of the total. Reporting peaked in 2019 at $142,493 and has fallen 96.5% since, to $4,988 in 2025. Among cardiovascular disease clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 474 payments — averaging $461.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$110K
- Amarin Pharma, Inc.$27K
- Boehringer Ingelheim$22K
- Sanofi-aventis U.S. LLC$18K
- Abbott$9K
- Atricure, Inc.$8K
- plus $25K from 27 others
What the payments were for
- Consulting fees$72,36133%
- Speaking & faculty fees$99,64246%
- Travel & lodging$28,61413%
- Food & beverage$16,3727%
- Education$1,8401%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 138 | $109,992 |
| Amarin Pharma, Inc. | 29 | $26,730 |
| Boehringer Ingelheim | 13 | $21,658 |
| Sanofi-aventis U.S. LLC | 8 | $18,416 |
| Abbott | 43 | $8,910 |
| Atricure, Inc. | 13 | $7,840 |
| ZOLL Respicardia, Inc. | 5 | $4,162 |
| Altathera Pharmaceuticals LLC | 5 | $4,016 |
| AstraZeneca | 3 | $3,514 |
| Boston Scientific | 49 | $3,332 |
| Biosense Webster, Inc. | 53 | $3,216 |
| Medtronic(2 entities) | 27 | $2,241 |
| Impulse Dynamics (USA) Inc. | 11 | $881 |
| Irhythm Technologies, Inc. | 4 | $734 |
| Infobionic, Inc | 5 | $450 |
| Artivion, Inc. | 1 | $400 |
| Johnson & Johnson | 13 | $359 |
| Cardiva Medical, Inc. | 2 | $224 |
| E.r. Squibb & Sons, L.L.C. | 6 | $223 |
| Boehringer Ingelheim International GmbH | 1 | $214 |
| Biotronik Inc. | 4 | $211 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $197 |
| Elutia, Inc. | 7 | $194 |
| Philips North America LLC | 4 | $169 |
| Aidoc Medical Ltd | 1 | $131 |
| Amgen | 7 | $102 |
| Novartis | 6 | $91 |
| CSL Behring | 1 | $80 |
| Pfizer | 4 | $56 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Novo Nordisk | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Cook Medical LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NORTHERA$99,698
- Vascepa$26,162
- MULTAQ$9,468
- SYNERGY ABLATION SYSTEM$7,301
- ATRICURE CRYOICE CRYOABLATION SYSTEM (CRYO2)$7,301
- EnSite Precision Cardiac Mapping System$4,200
- remede System$4,085
- Sotalol Hydrochloride$3,983
- DISEASE STATE$3,880
- LOKELMA$3,500
- ENSITE$1,862
- Carto 3$1,228
- PRADAXA$1,205
- Arctic Front$1,113
- AVEIR$909
- RHYTHMIA$851
- ZIO Patch$626
- OPTIMIZER$606
- ON-X AORTIC HEART VALVE WITH CONFORM-X SEWING RING AND EXTENDED HOLDER$400
- MoMe Kardia$289
How this compares
$218,829 in reported general payments places this provider in the 95th percentile of 142 cardiovascular disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 116 | $99,795 |
| XareltoRivaroxaban | 18 | $26,105 |
| EntrestoSacubitril/Valsartan | 19 | $14,631 |
| Dofetilide | 23 | $7,405 |
| Flecainide Acetate | 76 | $2,417 |
| Metoprolol Succinate | 91 | $998 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 33 | $618 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $424 |
| Amiodarone Hcl | 19 | $299 |
| SotalolSotalol Hcl | 18 | $258 |
| Lisinopril | 20 | $59 |
| Hydrochlorothiazide | 15 | $34 |
| Spironolactone | 11 | $26 |
| Atenolol | 11 | $23 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $56 | $99,795116 claims |
| Johnson & JohnsonXarelto | $359 | $26,10518 claims |
| NovartisEntresto | $91 | $14,63119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 142 cardiovascular disease providers in Iowa.
Other cardiovascular disease in Iowa City
- Jennifer RobinsonIowa City$37K
- Kimberly StaffeyIowa City$7K
- Aaron SifuentesIowa City$5K
- Suvasini LakshmananIowa City$4K
- Rakesh PonnapureddyIowa City$3K
- Corina IorgoveanuIowa City$2K
- Michael HajduIowa City$2K
- Boniface MalanguIowa City$2K
- Ferhaan AhmadIowa City$2K
- Brett JohnsonIowa City$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.